NQO1 and NRF2 may be valuable biomarkers for early diagnosis, prognostic, and therapeutic strategies in patients with cervical and endometrial carcinomas, in line with additional research showing that NRF2 overexpression was significantly associated with high-grade and advanced-stage endometrial and ovarian carcinomas (Cho et al., 2017; Tossetta et al., 2022; Tossetta and Marzioni, 2023). Here, NFE2L2 is linked to ovarian carcinoma.